UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price hit a new 52-week low on Tuesday. The company traded as low as $111.47 and last traded at $111.5325, with a volume of 12,542 shares traded. The stock had previously closed at $113.96.
Wall Street Analyst Weigh In
UCBJY has been the topic of a number of research reports. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Report on UCB
UCB Stock Performance
The firm has a fifty day simple moving average of $121.89 and a two-hundred day simple moving average of $136.06.
About UCB
UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.
UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.
Further Reading
- Five stocks we like better than UCB
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
